Literature DB >> 33381475

Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease.

Xin Chi1,2, Calvin Q Pan1,3, Shunai Liu2, Danying Cheng1, Ziwen Cao4, Huichun Xing1.   

Abstract

When alcohol-related liver disease occurs, the number and composition ratio of intestinal microorganisms will accordingly change. The alcohol-induced changes in the intestinal microbiota play a pivotal role in the process of developing the alcohol-related liver disease through the translocation of microbial products due to increased intestinal permeability. In recent years, therapeutic interventions with a concentration on regulating intestinal microbiota have been conducted for patients with alcohol-related liver disease. We aimed to provide a critical review and updates on the prevention and treatment of alcohol-related liver disease through regulating intestinal microbiota. A literature search was performed on the PubMed database for studies published in English about the therapeutic intervention with microbiota using animal models and patients with alcohol-related liver disease (1/2010-4/2020). The accumulating pieces of evidence suggest that the therapeutic use of probiotics, prebiotics, antibiotics, phages, or fecal microbial transplantation may have several influences on alcohol-related liver disease patients. Emergent data unveiled that these interventions can further regulate the composition of intestinal microbiota, minimize the negative impact of microbiota on the liver, and prevent disease progression from mild to severe alcoholic hepatitis, fibrosis, cirrhosis, or even liver cancer. The current review provides updates on the advances of therapeutic interventions with the effects of regulating intestinal microbiota on patients who have alcohol-related liver disease. In addition, the data gaps and research directions on further exploration of the role of intestinal microbiota for the management of the alcohol-related liver disease are also discussed.
Copyright © 2020 Xin Chi et al.

Entities:  

Year:  2020        PMID: 33381475      PMCID: PMC7759392          DOI: 10.1155/2020/6629196

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  4 in total

Review 1.  Gut Microbiome and Alcohol-associated Liver Disease.

Authors:  Cyriac A Philips; Bernd Schnabl; Jasmohan S Bajaj
Journal:  J Clin Exp Hepatol       Date:  2022-01-04

Review 2.  Comparative Analysis of the Microbiome across the Gut-Skin Axis in Atopic Dermatitis.

Authors:  Dong Hoon Park; Joo Wan Kim; Hi-Joon Park; Dae-Hyun Hahm
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 3.  Colostrum Therapy for Human Gastrointestinal Health and Disease.

Authors:  Kanta Chandwe; Paul Kelly
Journal:  Nutrients       Date:  2021-06-07       Impact factor: 5.717

Review 4.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.